SCHEMBL3479993

SCHEMBL3479993

O=C(NCc1ccc(S(=O)(=O)N2CCN(CC(O)N3CCOCC3)CC2)s1)c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK9 P45984 1/20 0.51
▸ MAPK10 P53779 1/20 0.51
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ POLB P06746 4/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ BCL2 P10415 1/20 0.45
▸ BCL2L1 Q07817 1/20 0.45
▸ LMNA P02545 2/20 0.45
▸ HTR1A P08908 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ CD274 Q9NZQ7 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2428407 0.84 MAPK9 (0.53) MAPK9MAPK10MEN1KMT2APOLB
SCHEMBL2423054 0.81 MAPK9 (0.59) MAPK9MAPK10MEN1KMT2APOLB
SCHEMBL2428799 0.80 MAPK9 (0.61) MAPK9MAPK10MEN1KMT2APOLB
SCHEMBL3480648 0.80 MAPK9 (0.60) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL7894669 0.79 MAPK9 (0.59) MAPK9MAPK10MEN1KMT2APOLB
SCHEMBL6431701 0.79 MAPK9 (0.59) MAPK9MAPK10MEN1KMT2APOLB
SCHEMBL3479879 0.79 MAPK9 (0.55) MAPK9MAPK10MEN1KMT2APOLB
SCHEMBL2424858 0.79 MAPK9 (0.61) MAPK9MAPK10MEN1KMT2APOLB
SCHEMBL2421342 0.78 MAPK9 (0.56) MAPK9MAPK10MEN1KMT2APOLB
SCHEMBL2423853 0.78 MAPK9 (0.54) MAPK9MAPK10MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 — — US disclosed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes CBR3, INSR, CS MAPK9 2768/4885MAPK10 1940/4885MEN1 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback